Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Genetix Pharmaceuticals completes $35mm Series B financing

Executive Summary

First-time investors Third Rock Ventures and Genzyme Ventures teamed up with returning backers TVM Capital, Forbion, and Easton Capital for gene delivery firm Genetix Pharmaceuticals' $35mm Series B round. Nick Leschly, a partner from Third Rock, has been named the company's interim president, and a member from Genzyme Ventures joined the board.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies